Cenix BioScience Follows up Successful RNAi-based Target Discovery Screens with Target Validation Study for AstraZeneca.
News Mar 20, 2009
The new project will focus on detailed cell-based studies to further advance the validation of novel oncology target candidates successfully identified by Cenix in screens completed recently for AstraZeneca. Both the original screens and the new validation work are driven by the core Cenix expertise in combining high throughput RNAi-based gene silencing with high content phenotypic analyses. Cenix will adapt and implement multi-parametric microscopybased analyses of RNAi-induced loss-of-function phenotypes using the Cellenger image analysis platform from Munich-based Definiens, to generate detailed insights into the cellular functions and therapeutic development potential of tested genes.
“We view the success of these first quite ambitious screens now completed for our colleagues at AstraZeneca as a clear testament to the strong scientific, technical and strategic synergies jointly achieved between our two teams,” said Dr. Christophe Echeverri, CEO/CSO of Cenix.
“We welcome the chance to continue assisting AstraZeneca in the crucially important process of target validation to further advance their oncology pipeline.”
Such RNAi datasets, now widely favored throughout the industry, offer a highly predictive and cost-effective basis for discovering and prioritizing targets for therapeutic drug development in a wide range of disease fields.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.